Niraparib Efficacy in Relapsed MesOthelioma (NERO). A Randomised Phase II trial of Niraparib versus active symptom control in Patients with Relapsed Malignant Mesothelioma
Gareth Griffiths is Professor of Clinical Trials and directs our Southampton Clinical Trials Unit. He works with clinicians, research groups and other scientists in the development of important clinical trials and other well-designed studies that aim to improve the treatment of a range of cancers and other diseases, and early diagnosis of cancer.
His works spans the different phases of clinical trials, from small dose finding and safety studies involving a handful of patients to larger trials of hundreds of patients looking at whether the treatments are better than the current standard treatments. His early diagnosis studies include thousands of patients looking at new ways to detect cancer early. Ultimately, these studies could help change the way that patients are treated for the better, by creating the evidence so as the new treatments becomes the standard of care for future patients treated in the NHS.
